EGFR and inflammatory bowel disease: In the last decade, evidence from animal models has suggested that UDCA may have a chemoprotective role against CRC in patients with IBD via the activation of Erk1/2, the suppression of c-Myc expression, the inhibition of the epidermal growth factor receptor (EGFr), the TGR5-YAP axis, and the regulation of intracellular ROS generation [44,45,46].